STATE OF MICHIGAN
DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS
BUREAU OF PROFESSIONAL LICENSING
BOARD OF MEDICINE
DISCIPLINARY SUBCOMMITTEE

In the Matter of

DAN G. GUYER, M.D. License No. 43-01-030688, Respondent.

File No. 43-15-137965

## CONSENT ORDER

On February 24, 2017, the Department of Licensing and Regulatory Affairs executed an Administrative Complaint charging Respondent with violating the Public Health Code, MCL 333.1101 *et seq*.

Respondent has admitted that the facts alleged in the Complaint are true and constitute violation(s) of MCL 333.16221(a) and (b)(i). The Board of Medicine's Disciplinary Subcommittee (DSC) has reviewed this Consent Order and Stipulation and agrees that the public interest is best served by resolution of the outstanding Complaint.

Therefore, IT IS FOUND that the facts alleged in the Complaint are true and constitute violation(s) of MCL 333.16221(a) and (b)(i).

Accordingly, IT IS ORDERED that for the cited violation(s) of the Public Health Code, Respondent is REPRIMANDED.

Page 1 of 5

IT IS FURTHER ORDERED that for the cited violation(s) of the Public Health Code, Respondent is placed on probation for a minimum of one day, not to exceed six months. The terms of probation shall be as follows:

1. CONTINUING EDUCATION: Respondent shall successfully complete and submit satisfactory evidence of completing pre-approved continuing education accepted by the Board in the area of neuropsycho pharmacology. This continuing education shall not apply in computing Respondent's current continuing education requirements for license renewal.

Respondent shall seek and obtain pre-approval of the continuing education from the Chairperson of the Board or the Chairperson's designee. Respondent shall mail requests for pre-approval and proof of the successful completion of the continuing education to: Department of Licensing and Regulatory Affairs, Enforcement Division, Compliance Section, P.O. Box 30670, Lansing, MI 48909.

The timely filing of all information relating to this Order shall be Respondent's responsibility, and failure to file the required information within the time limitations herein provided shall be deemed a violation of an order of the Board.

- 2. COMPLIANCE WITH THE PUBLIC HEALTH CODE: Respondent shall comply with all applicable provisions of the Public Health Code and rules promulgated under the Public Health Code.
- COSTS. Respondent shall be solely responsible for payment of all costs incurred in complying with the terms of this Order.

IT IS FURTHER ORDERED that Respondent shall be automatically discharged from probation at the end of the probationary period, PROVIDED Respondent has paid the fine as set forth below, has complied with the terms of this Order and has not violated the Public Health Code.

IT IS FURTHER ORDERED that for the cited violation(s) of the Public

Health Code, Respondent is FINED \$4,000.00 to be paid to the state of Michigan within

60 days of the effective date of this Order.

IT IS FURTHER ORDERED that the fine shall be mailed to the Department

of Licensing and Regulatory Affairs, Enforcement Division, Compliance Section, P.O. Box

30189, Lansing, MI 48909. The fine shall be paid by check or money order made payable

to the State of Michigan, and the check or money order shall clearly display file number

43-15-137965.

IT IS FURTHER ORDERED that if Respondent fails to comply with the

terms and conditions of this Order, Respondent's license shall be automatically

suspended for a minimum of one day. If, within six months of the suspension of the

license. Respondent complies with the terms of this Order, the license shall be

automatically reinstated.

IT IS FURTHER ORDERED that if Respondent's license remains

suspended for more than six months, Respondent must apply for reinstatement of the

license. If Respondent applies for reinstatement of the license, application for

reinstatement shall be in accordance with sections MCL 333.16245 and 333.16247.

IT IS FURTHER ORDERED that this Order shall be effective on the date

signed by the DSC or authorized representative, as set forth below.

Page 3 of 5

Dated: 3/2/18

MICHIGAN BOARD OF MEDICINE

DISCIPLINARY SUBCOMMITTE

Cheryl Wykoff Pezon Acting Director Bureau of Professional Licensing

Authorized Representative

## **STIPULATION**

The facts alleged in the Complaint are true and constitute violation(s)
 of MCL 333.16221(a) and (b)(i).

2. Respondent understands and intends that by signing this Stipulation Respondent is waiving the right, pursuant to the Public Health Code, the rules promulgated thereunder, and the Administrative Procedures Act, MCL 24.201 *et seq.*, to require the Department to prove the charges set forth in the Complaint by presentation of evidence and legal authority, and Respondent is waiving the right to appear with an attorney and such witnesses as Respondent may desire to present a defense to the charges.

3. This matter is a public record required to be published and made available to the public pursuant to the Michigan Freedom of Information Act, MCL 15.231 et seq., and this action will be reported to the National Practitioner Data Bank and any other entity as required by state or federal law, in accordance with 42 USC 11101-11152.

4. This Order was proposed by the DSC at a scheduled meeting held in Lansing, Michigan January 17, 2018. It is approved as to form and substance by Respondent and the Department and may be entered as the final order of the DSC in this matter.

AGREED TO BY:	AGREED TO BY:
Chllyleftin	Ola I Suya no
Cheryl Wykoff Pezon Acting Director	Dan G. Guyer, M.D.
Bureau of Professional Licensing	Respondent
Department of Licensing and	
Regulatory Affairs	- P 1.
Dated: 3/4//8	Dated: 2/27/18
/ / ·	
	Approved as to form by:
	John Toth (P33608)
	Attorney for Respondent/
	Dated: 0/28/18
· CC ·	

STATE OF MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS BUREAU OF PROFESSIONAL LICENSING

BOARD OF MEDICINE DISCIPLINARY SUBCOMMITTEE

In the Matter of

DAN G. GUYER, M.D.

License Number: 43-01-030688

File Number: 43-15-137965

ADMINISTRATIVE COMPLAINT

The Michigan Department of Licensing and Regulatory Affairs

(Complainant) by Kim Gaedeke, Director, Bureau of Professional Licensing, files this

Complaint against Dan G. Guyer, M.D. (Respondent) as follows:

The Michigan Board of Medicine (Board) is an administrative agency 1.

established by the Public Health Code, MCL 333.1101 et seq. Pursuant to section 16226

of the Public Health Code, supra, the Board's Disciplinary Subcommittee is empowered

to discipline licensees for violations of the Public Health Code.

Respondent is licensed to practice medicine in the state of Michigan 2.

and has a controlled substance license.

Lorazepam and Valium are schedule 4 controlled substances. 3.

Cogentin, Lexapro, Lithium, and Melatonin, Mellaril, and Risperdal are prescription

medications.

Administrative Complaint File Number: 43-15-137965

Page 1 of 6

At all relevant times, Respondent was engaged in private practice

and partner at Psychiatric Services of Grosse Pointe (facility) in Grosse Pointe, Michigan.

5. On September 26, 2013, Respondent saw patient M.R. (initials are

used throughout to protect the patient's identity), a 63-year-old male for evaluation and

potential changes to patient M.R.'s medication regimen as prescribed by another

physician. Patient M.R.'s medication regime consisted of Melatonin; Lithium 300 mg

three times per day; Lorazepam 1 mg three times per day; Risperdal 2 mg two times per

day; Cogentin and Mellaril 40 mg during the day and 100 mg at bedtime. Respondent

discontinued the Cogentin and Melatonin and decreased Lithium 300 mg to two times per

day and decreased Mellaril to 100 mg at bedtime only, and increased Risperdal to 3 mg

at bedtime. Respondent provided patient M.R. with 30-day prescriptions for Lithium,

Mellaril, Risperdal, and Lorazepam.

On October 4, 2013, Respondent saw patient M.R. for complaints of

dehydration. Respondent decreased patient M.R.'s Mellaril to 50 mg at bedtime.

7. On October 9, 2013, Respondent was informed that patient M.R. had

been admitted to the hospital and Mellaril had been discontinued. On October 11, 2013,

Respondent was contacted by hospital staff to decrease patient M.R.'s Lithium to one

time per day. Respondent increased patient M.R.'s Lithium to three times per day and

replaced Lorazepam with Valium.

On October 28, 2013, Respondent saw patient M.R. and made no

changes to patient M.R.'s medication regime.

9. On November 27, 2013, Respondent saw patient M.R. and made no

changes to patient M.R.'s medication regime. Respondent wrote a prescription for

Risperdal 3 mg and Lithium 300 mg with one refill.

10. Between September 2013 and December 2013, contrary to the

accepted standards of care for Lithium monitoring, Respondent failed to order laboratory

tests for patient M.R.

11. On January 28, 2014, Respondent saw patient M.R. for complaints

of behavior changes such as yelling, hitting, and not sleeping. Respondent titrated patient

M.R.'s Valium medication and ordered laboratory tests for Lithium levels 12 hours after

last dose, thyroid study (TSH) and two kidney studies (BUN and Creatinine).

12. On March 18, 2014, Respondent received patient M.R.'s laboratory

test results that revealed a BUN level of 13 (normal range 10-25 mg/dL); Creatinine level

of 0.95 (normal range <1.13 mg/dL); TSH level of 2.29 (normal range 0.30-5.00 uIU/mL),

and Lithium level of 1.2 (normal range 0.6-1.2 mmol/L). Respondent failed to address

patient M.R.'s Lithium level.

13. On May 19, 2014, Respondent saw patient M.R. for complaints of

behavior changes such as yelling and slamming doors. Respondent did not make any

changes to patient M.R.'s medication regime. Respondent failed to address patient

M.R.'s declining health.

On September 27, 2014, patient M.R.'s guardian informed 14.

Respondent that patient M.R. was depressed and would not leave his home. Respondent

prescribed Lexapro 10 mg at bedtime. Respondent failed to address patient M.R.'s

declining health.

On December 18, 2014, Respondent provided patient M.R. 15.

prescriptions for his medications. Contrary to the accepted standards of care for Lithium

monitoring, Respondent failed to order laboratory tests for patient M.R.

On January 21, 2015, Respondent saw patient M.R. for complaints 16.

of falling and significant weight loss. Respondent discontinued patient M.R.'s Lexapro

and made no changes to patient M.R.'s other medications.

On February 17, 2015, a physician from Henry Ford West Bloomfield 17.

Hospital informed Respondent that patient M.R. had been admitted to the hospital and

was diagnosed with acute onset Lithium toxicity. Laboratory tests revealed patient M.R.

had a Lithium toxicity level of 3.3. Prior to patient M.R.'s hospital discharge his Lithium

level was 0.5.

On May 16, 2016, during an interview with Complainant's 18.

investigator, Respondent stated that his standard protocol was to order laboratory tests

Administrative Complaint

Page 4 of 6 File Number: 43-15-137965

for Lithium levels yearly and that patients or family members could call Respondent

anytime if any problems presented.

COUNT I

Respondent's conduct, as set forth above, evidences a violation of general

duty, consisting of negligence or failure to exercise due care, including negligent

delegation to or supervision of employees or other individuals, whether or not injury

results, in violation of section 16221(a) of the Public Health Code, supra.

COUNT II

Respondent's conduct, as set forth above, evidences a departure from, or

failure to conform to, minimal standards of acceptable and prevailing practice for the

health profession, whether or not actual injury to an individual occurs, in violation of

section 16221(b)(i) of the Public Health Code, supra.

Complainant requests that this Complaint be served upon Respondent and

that Respondent be offered an opportunity to show compliance with all lawful

requirements for retention of the license. If compliance is not shown, Complainant further

requests that formal proceedings be commenced pursuant to the Public Health Code,

rules promulgated thereunder, and the Administrative Procedures Act, MCL 24.201 et

seq.

Pursuant to section 16231(8) of the Public Health Code, supra, Respondent

has 30 days from the date of receipt of this Complaint to submit a written response to the

allegations contained herein. The written response shall be submitted to Complainant,

Kim Gaedeke, Director, Bureau of Professional Licensing, Department of Licensing and

Regulatory Affairs, P.O. Box 30670, Lansing, MI 48909.

Pursuant to section 16231(9) of the Public Health Code, supra,

Respondent's failure to submit a written response within 30 days, as noted above, shall

be treated as an admission of the allegations contained herein and shall result in

transmittal of this Complaint directly to the Board's Disciplinary Subcommittee for

imposition of an appropriate sanction.

Dated:

Kim Gaedeke, Director

Bureau of Professional Licensing

LFM